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Background. We performed a retrospective study to assess whether the initial molecular characteristics of glioblastomas (GBMs)
were associated with the response to the bevacizumab/irinotecan chemotherapy regimen given at recurrence. Results. Comparison
of the genomic and gene expression profiles of the responders (𝑛 = 12) and nonresponders (𝑛 = 13) demonstrated only slight
differences and could not identify any robust biomarkers associated with the response. In contrast, a significant association was
observed between GBMs molecular subtypes and response rates. GBMs assigned to molecular subtype IGS-18 and to classical
subtype had a lower response rate than those assigned to other subtypes. In an independent series of 33 patients, neither EGFR
amplification nor CDKN2A deletion (which are frequent in IGS-18 and classical GBMs) was significantly associated with the
response rate, suggesting that these two alterations are unlikely to explain the lower response rate of theseGBMsmolecular subtypes.
Conclusion. Despite its limited sample size, the present study suggests that comparing the initial molecular profiles of responders
and nonresponders might not be an effective strategy to identify biomarkers of the response to bevacizumab given at recurrence.
Yet it suggests that the response rate might differ among GBMs molecular subtypes.
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1. Background
In recurrent glioblastomas (GBMs), studies have shown a
high response rate (30–50%) to bevacizumab, a humanmon-
oclonal antivascular endothelial growth factor (VEGF) anti-
body, administered alone or in combination with irinotecan,
demonstrating a 35–50% estimated 6-month progression-
free survival (PFS) [1–3]. Simple biomarkers that would help
in selecting patients most likely to benefit from bevacizumab
would be very helpful, but no such markers are available to
date. In the present study, we hypothesized that the response
to bevacizumab plus irinotecan given at recurrence might be
related to the molecular characteristics of the initial tumor.
To identify predictive biomarkers, we compared the initial
GBMgenomic and gene expression profiles of responders and
nonresponders to bevacizumab plus irinotecan given at the
time of recurrence.
2. Methods
2.1. Patients. We retrospectively identified responders and
nonresponders to bevacizumab/irinotecan chemotherapy.
This study was approved by the ANOCEF review board. All
patients who underwent a genetic analysis of tumor samples
collected for this study signed a written informed consent
form.The patients’ clinical characteristics are summarized in
Table 1 and see additional Table 1 in Supplementary Material
available online at http://dx.doi.org/10.1155/2014/282815. All
of the 25 patients included in this study had de novo GBM
according to the 2007 World Health Organization Classifi-
cation [4] and were initially treated according to the Stupp
regimen [5]. To exclude patients with possible pseudopro-
gression, only those patients with a progression occurring
more than 3 months after the end of the radiochemotherapy
treatment were selected [6]. Patients received bevacizumab
(10mg/kg) plus irinotecan (125mg/m2) every two weeks
either at the first (𝑛 = 15), second (𝑛 = 9), or third
(𝑛 = 1) recurrence (chemotherapy details are available
in additional Table 1). To identify clinically meaningful
biomarkers of the response, the patients were considered to
be responders if they achieved a complete or partial response
according to RANO criteria [6] and presented more than
6-month progression-free survival (PFS); the patients were
considered to be nonresponders if they progressed within 4
months.
2.2. Samples. The samples were provided as snap-frozen
sections of the areas immediately adjacent to the region
used for the histopathological diagnosis. Only samples rep-
resentative of the tumor and from which high-quality DNA
and/or RNA could be obtained were selected (𝑛 = 25). A
total of 21 samples were available for the genomic Illumina
SNP array study, which included samples from 8 responders
and 13 nonresponders. The gene expression array study was
performed on 23 samples (including 19 samples common to
the SNP array study): 11 responders and 12 nonresponders.
2.3. Genomic and Gene Expression Data
2.3.1. RNA and DNA Extraction. Total RNA was extracted
using the RNeasy Lipid Tissue Mini Kit (Qiagen), and
DNA was extracted using the QIAamp DNA Mini Kit
(Qiagen) following the manufacturer’s instructions. Both
the RNA and DNA were assessed for integrity and quan-
tity, following stringent quality control criteria (CIT pro-
gramprotocols http://cit.ligue-cancer.net/).The genomic and
gene expression analyses were performed using R software
(http://www.R-project.org/).
2.3.2. Gene Expression Arrays. The gene expression arrays
were performed using the IGBMC microarray platform
(Strasbourg, France). Total RNA was amplified, labeled,
and hybridized to the Affymetrix Human Genome U133
plus2 GeneChip, following the manufacturer’s protocol
(Affymetrix, Santa Clara, CA, USA). The microarrays were
scanned using an Affymetrix GeneChip Scanner 3000, and
the raw intensities were quantified from the subsequent
images using GCOS 1.4 software (Affymetrix). The data
were normalized using the robust multiarray averagemethod
implemented in the R package affinity [9].
Unsupervised hierarchical clustering analysis was per-
formed using the Pearson correlation metric. Only probesets
with an Affymetrix annotation class A and located on
autosomes were considered. Differences between the sample
clusters were tested using the Chi-squared test, and genes
differentially expressed between the tumors of responder and
nonresponder patients were assessed using the 𝑡-test followed
by Benjamini and Hochberg correction. The analyses of the
gene sets using KEGG and Biocarta pathways and Gene
Ontology terms, Molecular Signature Database gene sets,
and Stanford Microarray Database gene sets were performed
on the 1000 most differentially expressed genes (500 genes
upregulated in responders and 500 genes upregulated in
nonresponders) using hypergeometric tests [10]. We used
the published centroid-based classifier of Verhaak et al. to
classify our samples according to their system [7]. Samples
were assigned to one of the six molecular subtypes of
gliomas (called intrinsic glioma subtypes (IGS)) described
by Gravendeel et al. [8] using ClusterRepro (an R package;
http://crantastic.org/packages/clusterRepro) [11].
2.3.3. Genomic Arrays. The genomic arrays were performed
using the IntegraGen Platform (Evry, France). DNA was
hybridized to Illumina SNPHumanCNV370 chips according
to the instructions provided by the array manufacturer
(Illumina, San Diego, CA). The raw fluorescent signals were
imported into Illumina BeadStudio software and normalized
as previously described [12] to obtain the log R ratio (LRR)
and B Allele Frequency (BAF) for each SNP. A supplemental
normalization procedure tQN [13] was applied to correct for
dye bias.The genomic profiles were then segmented using the
circular binary segmentation algorithm (DNAcopy package,
Bioconductor) [14] into the LRR and BAF data separately, as
previously described [13, 15]. The absolute copy number and
genotype status of the segments were then determined using
the genome alteration print (GAP) method [15].
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Table 1: Patient characteristics.
Nonresponders Responders
Number of patients 13 12
Median age (years) at diagnosis (range) 56 (37–69) 62 (57–72) t-test P = 0.01
Biopsy/resection (%) 0/100 25/75
Initial treatment (%) RTCT (100%) RTCT (100%)
Median delay (months) between diagnosis and bev./iri. onset (range) 11 (7–22) 13 (5–27) Ns




Median KPS at bev./iri. onset 70 80 Ns
Median PFS after bev./iri. onset (months) 2.4 9.4 P < 0.0001
Median OS after bev./iri. onset (months) 6.4 18.9 P = 0.0001
Median OS since diagnosis (months) 18.3 36.4 P = 0.002
RTCT: temozolomide radiochemotherapy; bev./iri.: bevacizumab/irinotecan chemotherapy; KPS: Karnofsky performance status; PFS: progression-free
survival; OS: overall survival; ns: not significant.
The data are available in the ArrayExpress database
(http://www.ebi.ac.uk/arrayexpress/), ArrayExpress acces-
sion: E-MTAB-951.
2.3.4. RT-PCR. The gene expression of NPTX2, EPHA7,
SOCS2, PDGFD, PRKCZ, and ENPP4 in the tumors and
nontumor control tissue were analyzed using UPL probe
real-time quantitative polymerase chain reaction (QPCR)
analysis. The reference gene was PPIA. The sequences of
the primers and probes are listed in additional Table 2. The
real-time QPCR reactions were performed as follows: 1X
LightCycler 480 Probes Master (Roche Applied Science), 4
pmoles each primer, 2 pmoles Universal ProbeLibrary Set,
Human, and 8 ng cDNA. The real-time QPCR cycles were as
follows: initial denaturation at 95∘C for 110 minutes and 45
cycles of 95∘C for 10 seconds and annealing at 60∘C for 30
minutes.The 2-DeltaDeltaCTmethod was used to determine
the relative expression levels. The calculation of the relative
amounts of the studied transcript compared to the reference
transcript was performed using the LightCycler 480 Software
(Roche applied science). The final results were expressed as a
ratio of the expression levels of the studied gene and reference
in the sample, normalized to the ratio of the reference gene
expression in the calibration RNA.
2.4. Independent Data Set. An independent series of
33GBMs from the Salpeˆtrie`re database treated with the
bevacizumab/irinotecan combination at recurrence (31 out
of 33 were treated at first recurrence) was used to assess the
impact of the CDKN2A homozygous deletion and EGFR
amplification. These alterations were assessed in the initial
tumor using CGH arrays as previously described [16]. The
response according to RANO criteria was assessable in 29 of
the patients. RNA was available for 7 of the responders and
11 nonresponders and was used to study NPTX2, EPHA7,
SOCS2, PDGFD, PRKCZ, and ENPP4 gene expression using
RT-PCR.
3. Results
3.1. Patients’ Characteristics. Twelve responders and thir-
teen nonresponders were included. All of the MRIs were
reviewed. All of the patients exhibited an evaluable disease
at the initiation of bevacizumab plus irinotecan treatment.
The patients’ characteristics are shown in Table 1. After
bevacizumab/irinotecan onset, the responders had a longer
progression-free survival (PFS) and overall survival (OS)
than the nonresponders. The OS since diagnosis was also
significantly longer for the responders (Table 1).
3.2. Responders and Nonresponders Have Very Similar
Genomic and Gene Expression Profiles. The comparison of
the genomic profiles (gains, losses, homozygous deletions,
and amplifications) of the responders (𝑛 = 8) versus
nonresponders (𝑛 = 13) demonstrated only slight genomic
differences (Figure 1, additional Tables 3a and 3b), with the
most consistent being an entire chromosome 20 gain that was
significantly more frequent in the nonresponders (Fisher’s
exact test 𝑃 = 0.04). EGFR amplification (9/13 in non-
responders versus 4/8 in responders) and CDKN2A locus
homozygous deletion (8/13 in nonresponders versus 4/8 in
responders) were also more frequently observed in nonre-
sponders, but the difference was not significant.
Similarly, the comparison of the gene expression profiles
of the responders (𝑛 = 11) and nonresponders (𝑛 = 12)
demonstrated only few differences. Sixty probe sets (fifty-one
in responders and nine in nonresponders) were differentially
expressed, with a 𝑡-test𝑃 value< 0.05 and a fold change above
2, though with a very high (95%) false discovery rate (addi-
tional Table 4). Neither the expression of VEGF nor its recep-
tors were associatedwith the response to the treatment. Using
RT-PCR we studied the expression of 6 genes implicated
in angiogenesis and overexpressed in responders (ENPP4,
PRKCZ, and EPHA7) or nonresponders (NPTX2, SOCS2,
and PDGFD) in an independent series of 7 responders and
11 nonresponders. EPHA7 [17] is implicated in endothelial
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Figure 1: Genomic profiles of responders and nonresponders. Genomic profiles of responders and nonresponders to the beva-
cizumab/irinotecan regimen. For each chromosome, the telomere of the short arm is on the left and the telomere of the long arm is on
the right. The 𝑦-axis corresponds to the frequency of gains and losses in each group of patients.
tubulogenesis, and PRKCZ has been implicated in VEGF
transcriptional activation [18]. NPTX2 has been shown to be
overexpressed in edematous versus nonedematous gliomas in
the absence of increased VEGF expression [19]. PDGFD is a
proangiogenic factor [20], and SOCS2 is involved in IGF1R
signaling and is also a proangiogenic factor [21]. However,
with the exception of SOCS2, we failed to confirm similar
overexpression in the responders/nonresponders that was
significant in this independent series (additional Table 5).
Lastly, the pathway analysis performed on the 1000 genes that
were most differentially expressed (500 genes upregulated
in responders and 500 genes upregulated in nonresponders)
demonstrated that these gene lists were significantly enriched
in geneswith different ontologies (additional Tables 6 and 7).
The list of upregulated genes in the responders was signif-
icantly enriched in genes upregulated in the normal brain,
whereas the list of upregulated genes in the nonresponders
was enriched in genes that have been shown to be upregulated
during hypoxia [22] and also in genes that might be targets of
the transcription factor HIF1.
3.3. GBMs Molecular Subtypes Are Associated with Different
Response Rates. As responders and nonresponders had very
similar gene expression profiles, we hypothesized that there
might be several subgroups of responders and nonrespon-
ders. To test this hypothesis, we performed an unsupervised
hierarchical clustering analysis of the 23GBMs included
in the gene expression study. As shown in Figure 2, three
main subgroups were identified. This clustering was robust
and conserved across different gene lists and clustering
methods. However, none of the three clusters was enriched
in responders or nonresponders, and some responders and
nonresponders could have very similar gene expression pro-
files. Therefore, to assess whether transcriptomic subgroups
of GBMs previously identified in larger series of patients were
associated with a specific pattern of response to the beva-
cizumab/irinotecan regimen, we classified our 23 samples
according to the transcriptomic classifications of Gravendeel
et al. [8] and of Verhaak et al. [7] and estimated the response
rate in each subgroup. According to Gravendeel et al. [8],
14GBMswere assigned tomolecular subtype 18 (IGS-18), 3 to
molecular subtype 22 (IGS-22), and 6 to molecular subtype
23 (IGS-23). According to Verhaak et al. [7], 9 GBMs were
classified as classical, 6 as mesenchymal, 5 as proneural, and
3 as neural. The 9 classical GBMs were also assigned to IGS-
18 which in addition consisted of 3 neural and 2 proneural
GBMs. Interestingly, the GBMs assigned to IGS-18 weremore
frequently not responsive than the GBMs assigned to IGS-22
or IGS-23 (10/14 versus 2/9, Fisher’s exact test 𝑃 value = 0.03)
and a similar trend was observed for classical versus non-
classical GBMs (7/9 versus 5/14, Fisher’s exact test 𝑃 value =
0.09). Conversely, IGS-18GBMs had a shorter PFS after
bevacizumab/irinotecan than IGS-22/23GBMs (3.2 months
versus 9.4 months, 𝑃 = 0.01) and classical GBMs had
a shorter PFS than nonclassical GBMs (2.2 months versus
8.3 months, 𝑃 = 0.003) (Figure 3). Overall survival after
bevacizumab/irinotecan also tended to be shorter in IGS-18
than in IGS-22/23GBMs and in classical than nonclassical
GBMs (7 months versus 18.9 months, 𝑃 = 0.06 and 6.6
months versus 14.3 months, 𝑃 = 0.06).
3.4. Neither EGFR Amplification Status Nor CDKN2A Locus
Homozygous Deletion Status Is Associated with the Response
Rate, the Progression-Free Survival, or the Overall Sur-
vival after Bevacizumab/Irinotecan Initiation. Because, in
our series, EGFR amplification and CDKN2A homozygous
deletion were more frequent in IGS-18GBMs than in IGS-
22/23GBMs (11/14 versus 0/5, Fisher’s exact test 𝑃 value <0.01
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Figure 2: Unsupervised hierarchical clustering of the 23GBMs. The heatmap was constructed using the 2365 probesets (quantile 0.95),
with the greatest robust coefficient of variation between the tumor samples. The samples and genes were clustered using Ward’s linkage
and Pearson’s correlation coefficient. For each probe set, the lowest and highest intensity values are displayed in blue and red, respectively.
Response: black = responder, white = nonresponder. Verhaak = class according to Verhaak et al.’s classification [7]: neural = green, classical =



















































Figure 3: Progression-free survival according to Gravendeel et al. [8] and Verhaak et al. [7] molecular subtypes. GBMs assigned to IGS-18
(dashed line) had a shorter PFS after bevacizumab/irinotecan than those assigned to IGS-22 and IGS-23 (plain line) (3.2 months versus 9.4
months, 𝑃 = 0.01). GBMs classified as classical (dashed line) had a shorter PFS than those classified as nonclassical (2.2 months versus 8.3
months, 𝑃 = 0.003).
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Table 2: Characteristics of the 33 patients from the Salpeˆtrie`re
database for whom the impact of EGFR amplification and CDKN2A
locus homozygous deletion was assessed.
Characteristics of the 33 patients of the independent dataset
Number of patients 33
Median age (years) at diagnosis (range) 59 (25–81)
Initial treatment (%) RTCT (100%)
Median delay (months) between diagnosis and
bev./iri. onset (range) 15 (3.5–60)
Recurrence number at bev./iri. onset
First 31
Second/third 1/1







CDKN2A homozygous deletion 12
Median PFS after bev./iri. onset (months) 5.5
Median OS after bev./iri. onset (months) 9.7
Median OS since diagnosis (months) 29
RTCT: temozolomide radiochemotherapy; bev./iri.: bevacizumab/irinotecan
chemotherapy; KPS: Karnofsky performance status; PFS: progression-free
survival; OS: overall survival; ns, nonsignificant.
and 10/14 versus 1/5 Fisher’s exact test 𝑃 value = 0.1, resp.)
and alsomore frequent in classical than in nonclassical GBMs
(9/9 versus 2/10, Fisher’s exact test 𝑃 value < 0.01 and 10/14
versus 1/5 Fisher’s exact test 𝑃 value = 0.02, resp.), we decided
to evaluate the impact of these two genomic abnormalities
in an independent series, in order to assess if these genomic
abnormalities contribute to the lower response rate of IGS-
18 and classical GBMs. This independent series comprised
33GBMs from the Salpeˆtrie`re database treated with the
combination of bevacizumab/irinotecan at recurrence and
for whom the CDKN2A locus homozygous deletion and
EGFR amplification status were available in the initial tumor.
The patients’ characteristics are shown in Table 2. However,
we did not observe any significant association between
EGFR amplification and/or CDKN2A deletion status and the
response rate to bevacizumab/irinotecan, the PFS, or the OS
after bevacizumab/irinotecan initiation.
4. Discussion
Several studies have identified radiological, plasmatic, or
clinical markers of the response to bevacizumab [23–25].The
objective of the present study was to identify biomarkers
predictive of the response to bevacizumab/irinotecan given
at GBM recurrence based on the transcriptomic and genomic
characterization of the initial tumor. Given the dramatically
different clinical and radiological response patterns to this
treatment, we hypothesized that the comparison of a lim-
ited series of well-selected responders and nonresponders
would be sufficient to identify robust and clinically useful
biomarkers if such markers do exist. However, although the
responders and nonresponders had dramatically different
response patterns, we found that the two groups of patients
had very similar genomic and gene expression profiles
and we failed to identify any robust predictive biomarker.
There are several possible hypotheses to explain this finding.
First, the genomic and transcriptomic characteristics of
the initial tumor might not be predictive of the response
to bevacizumab/irinotecan given at recurrence because the
molecular profile of recurrent GBMsmight have significantly
changed. However, Sathornsumetee et al. demonstrated that
the expression of VEGF and CA9 (a marker of hypoxia)
assessed by immunohistochemistry in the initial GBM was
associated with the response and survival, respectively, in
patients receiving bevacizumab and irinotecan at recurrence
[26]. Interestingly, we similarly found that the profile of
nonresponders was enriched in genes upregulated during
hypoxia, though not influenced by VEGF expression. A
second hypothesis to explain the absence of major differ-
ence between the profiles of responders and nonresponders
is that the criteria used for defining the responders and
nonresponders in the present study were not appropriate.
These criteria were chosen to discover biomarkers that might
be clinically meaningful and that might identify responders
that achieve both a radiological response and prolonged PFS
(>6 months) and to differentiate these patients from those
who progress rapidly, regardless of the radiological response.
Another hypothesis (and we suggest the most likely) is that
the comparison of responders and nonresponders (regardless
of the criteria) might not be the best strategy to identify
biomarkers of the response. Indeed, this strategy assumes
that all of the responders and nonresponders share common
characteristics, which might be inappropriate if there are
not one but several subgroups of responders/nonresponders
with different mechanisms of response or resistance. In fact,
both Verhaak et al. and Gravendeel et al. demonstrated that
this is likely to be the case, as they identified transcrip-
tomic subgroups of GBMs that seem to display different
patterns of response according to the treatment used [7,
8]. Furthermore, we previously found that mesenchymal
GBMs were more likely to respond to radiotherapy, whereas
classical GBMs were more likely to respond to first-line
alkylating chemotherapy [10]. In our series, though it was
not designed to study this association, we observed an
interesting association between GBMs molecular classes and
the response rates. Using Gravendeel et al. classification,
GBMs assigned to IGS-18 had a lower response rate to
bevacizumab/irinotecan than the GBMs assigned to IGS-22
and IGS-23 [8]. Using Verhaak et al. classification a similar
trend was observed for classical GBMs [7] when compared
to nonclassical GBMs. This is in agreement with the fact that
IGS-18 GBMs are generally assigned to the classical subtype
(9 out of 14 cases in our series) [27]. As EGFR amplification
and CDKN2A deletion status are two genomic hallmarks of
IGS-18 and classical GBMs, we next studied the impact of
these two genomic abnormalities in an independent series
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of 33 patients. However, we did not identify any significant
association with the response rate to bevacizumab/irinotecan
suggesting that EGFR amplification and CDKN2A deletion
are not responsible for the lower response rate of IGS-18 and
classical GBMs to bevacizumab/irinotecan.
Taken together, our findings suggest that comparing
the initial genomic and gene expression profiles of respon-
ders and nonresponders might not be an effective strategy
to identify robust biomarkers of the response to beva-
cizumab/irinotecan given at recurrence. Yet, they also suggest
that GBMs molecular subclasses are associated with the
response to this treatment. This result however needs to be
validated in a prospective and larger series of patients.
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